Related Experiment Video
Updated: Jan 29, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs
Hiba Ahmad Zahreddine1, Biljana Culjkovic-Kraljacic1, Jadwiga Gasiorek1
1Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology , Université de Montréal , Montréal , Quebec , Canada.
Abstract:
Cancer therapies are plagued by resistance. Previously, we discovered a novel form of cancer drug resistance where the Glioma-associated protein 1 (GLI1) elevates UGT1A glucuronidation enzymes, thereby glucuronidating cytarabine and ribavirin, leading to resistance in leukemia patients. Here, we demonstrate that GLI1 imparts resistance to ∼40 compounds, including FDA-approved drugs with disparate chemotypes ( e.g., methotrexate and venetoclax). GLI1 indirectly elevates UGT1As via the chaperone calreticulin, which is required for resistance. Further, we demonstrate that resistant cells are more sensitive to ATP inhibitors, suggesting an Achilles' heel, which could be exploited in the future. In all, we identify GLI1-inducible glucuronidation as a broad-spectrum multidrug resistance pathway.
Insights
Glioma-associated protein 1 (GLI1) drives broad drug resistance in cancer by increasing glucuronidation enzymes. This pathway, involving calreticulin, offers a potential target for overcoming multidrug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer drug resistance is a major clinical challenge.
- Previously identified GLI1-mediated resistance to specific leukemia drugs via UGT1A enzymes.
Purpose of the Study:
- To investigate the broad spectrum of GLI1-induced drug resistance.
- To elucidate the mechanism of GLI1-mediated resistance.
- To identify potential therapeutic vulnerabilities in resistant cells.
Main Methods:
- Assessed GLI1's effect on resistance to a panel of compounds.
- Investigated the role of calreticulin in GLI1-mediated resistance.
- Examined the sensitivity of resistant cells to ATP inhibitors.
Main Results:
- GLI1 confers resistance to approximately 40 compounds, including methotrexate and venetoclax.
- Calreticulin is essential for GLI1-induced resistance.
- Resistant cancer cells exhibit increased sensitivity to ATP inhibitors.
Conclusions:
- GLI1-inducible glucuronidation represents a broad-spectrum multidrug resistance pathway.
- Calreticulin is a key mediator in this resistance mechanism.
- Targeting ATP pathways may overcome GLI1-driven drug resistance.
More Related Videos
Related Concept Videos
Phase II Reactions: Glucuronidation
The Electromagnetic Spectrum
The Electromagnetic Spectrum
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
IR Spectrum
Transmittance is defined as the ratio of the radiant power passing through a sample to that from the radiation's source. Multiplying the transmittance by 100 gives the percent transmittance (%T), which varies between 100% (no absorption) and 0%...
Mass Spectrum

